Abstract
Idiopathic pulmonary fibrosis (IPF) is a refractory disease that progresses from alveolar damage and inflammation to interstitial fibrosis. In this study, we confirmed the progress of the pathological condition of pulmonary fibrosis model in mice and investigated the effects of IPF therapeutic agent nintedanib ethanesulfonate (ofev).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings for Annual Meeting of The Japanese Pharmacological Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
